L
Lorraine A. Lebel
Researcher at Pfizer
Publications - 49
Citations - 3530
Lorraine A. Lebel is an academic researcher from Pfizer. The author has contributed to research in topics: Phosphodiesterase & Receptor. The author has an hindex of 22, co-authored 49 publications receiving 3381 citations.
Papers
More filters
Journal ArticleDOI
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Jotham Wadsworth Coe,Paige Roanne Palmer Brooks,Michael G. Vetelino,Michael C. Wirtz,Eric P. Arnold,Huang Jianhua,Steven B. Sands,Thomas I. Davis,Lorraine A. Lebel,Carol B. Fox,Alka Shrikhande,James Heym,Eric Schaeffer,Hans Rollema,Yi Lu,Robert S. Mansbach,Leslie K. Chambers,Charles C. Rovetti,David W. Schulz,and F. David Tingley,Brian T. O’Neill +20 more
TL;DR: Varenicline displays high α4β2 nAChR affinity and the desired in vivo dopaminergic profile and provides relief from the craving and withdrawal syndrome that accompanies cessation attempts.
Journal ArticleDOI
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Hans Rollema,Leslie K. Chambers,Jotham Wadsworth Coe,J. Glowa,Raymond S. Hurst,Lorraine A. Lebel,Yi Lu,Robert S. Mansbach,Robert J. Mather,Charles C. Rovetti,Steven B. Sands,Eric Schaeffer,David W. Schulz,F. D. Tingley,Kathryn E. Williams +14 more
TL;DR: The data suggest that varenicline can reproduce to some extent the subjective effects of smoking by partially activating α4β2 nAChRs, while preventing full activation of these receptors by nicotine.
Journal ArticleDOI
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
TL;DR: Certain members of this 4-amino[1,2,4]triazolo[4,3-a]quinoxaline series are among the most potent and A1 or A2 selective non-xanthine adenosine antagonists known.
Journal ArticleDOI
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
TL;DR: This unique pharmacological profile of ziprasidone may be related to its clinical effectiveness as a treatment for the positive, negative and affective symptoms of schizophrenia with a low propensity for extrapyramidal side effects, cognitive deficits and weight gain.
Journal ArticleDOI
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Judith A. Siuciak,Douglas S. Chapin,John F. Harms,Lorraine A. Lebel,Sheryl A. McCarthy,Leslie K. Chambers,Alka Shrikhande,Stephen K.-F. Wong,Frank S. Menniti,Christopher J. Schmidt +9 more
TL;DR: The results indicate that PDE10A regulates the activation of striatal medium spiny neurons through effects on cAMP- and cGMP-dependent signaling cascades and demonstrate that papaverine has efficacy in behavioral models predictive of antipsychotic activity.